TNFSF10 and cancer: In mouse xenograft models bearing human tumor cells lines, TRAIL and its agonistic antibodies directed against TRAIL receptors have been demonstrated to possess potent antitumor activity [234], supporting the idea of using these biological agents as a novel approach to cancer treatment and thereby mimicking some of the effector mechanisms normally employed by the immune system in its defense against transformed cells and potentially bypass the defective intrinsic (mitochondrial) pathway to apoptosis.